ALGS — Aligos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $33.32m
- -$23.46m
- $3.95m
Annual cashflow statement for Aligos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -109 | -128 | -96 | -87.7 | -131 |
| Depreciation | |||||
| Non-Cash Items | 15.5 | 14.3 | 15.9 | 16.6 | 54.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.1 | -4.65 | -1.55 | -9.53 | -4.96 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -74.3 | -116 | -79.4 | -79 | -80.7 |
| Capital Expenditures | -2.06 | -0.892 | -0.943 | -0.019 | -0.13 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 34.8 | 3.91 | -25.4 | 45 | -18.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 32.8 | 3.02 | -26.3 | 45 | -18.3 |
| Financing Cash Flow Items | -4.12 | -0.875 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 192 | 78.7 | 0.164 | 88.3 | 0.355 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 151 | -34 | -106 | 54.3 | -98.7 |